HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
NCT ID: NCT02916017
Last Updated: 2021-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
259 participants
OBSERVATIONAL
2016-11-15
2020-10-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants receiving adalimumab
Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
0 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Juntendo University Urayasu Hospital /ID# 168358
Urayasu-shi, Chiba, Japan
Matsuyama Red Cross Hospital /ID# 164149
Matsuyama, Ehime, Japan
Kyushu University Hospital /ID# 163042
Fukuoka, Fukuoka, Japan
Fukuoka University Hospital /ID# 163043
Fukuoka, Fukuoka, Japan
Kurume University Hospital /ID# 162945
Kurume-shi, Fukuoka, Japan
Gunma University Hospital /ID# 166916
Maebashi, Gunma, Japan
Hiroshima University Hospital /ID# 166915
Hiroshima, Hiroshima, Japan
Hokkaido University Hospital /ID# 163041
Sapporo, Hokkaido, Japan
Kobe University Hospital /ID# 165250
Kobe, Hyōgo, Japan
Duplicate_Kanazawa University Hospital /ID# 166914
Kanazawa, Ishikawa-ken, Japan
Yokohama Municipal Citizen's Hospital /ID# 161742
Yokohama, Kanagawa, Japan
Kochi Medical School Hospital /ID# 164144
Nankoku-shi, Kochi, Japan
Shinshu University Hospital /ID# 164153
Matsumoto-shi, Nagano, Japan
Niigata University Medical & Dental Hospital /ID# 169563
Niigata, Niigata, Japan
Osaka University Hospital /ID# 164147
Suita-shi, Osaka, Japan
Saitama Medical University Hospital /ID# 162944
Iruma-gun, Saitama, Japan
Dokkyo Medical University Hospital /ID# 164154
Shimotsuga-gun, Tochigi, Japan
Tokushima University Hospital /ID# 164145
Tokushima, Tokushima, Japan
Juntendo University Hospital /ID# 169564
Bunkyo-ku, Tokyo, Japan
Tokyo Medical And Dental University, Medical Hospital /ID# 165251
Bunkyo-ku, Tokyo, Japan
Nippon Medical School Hospital /ID# 166938
Bunkyo-ku, Tokyo, Japan
The University of Tokyo Hospital /ID# 162943
Bunkyo-ku, Tokyo, Japan
The Jikei University Hospital /ID# 164152
Minato-ku, Tokyo, Japan
Tokyo Medical University Hospital /ID# 164146
Shinjuku-ku, Tokyo, Japan
Center Hospital of the National Center for Global Health and Medicine /ID# 164148
Shinjuku-ku, Tokyo, Japan
Tokyo Women's Medical University Hospital /ID# 165248
Shinjuku-ku, Tokyo, Japan
Yamaguchi University Hospital /ID# 165249
Ube-shi, Yamaguchi, Japan
Kagoshima Uni Med and Dental /ID# 164150
Kagoshima, , Japan
Kakogawa Central City Hospital /ID# 167706
Kakogawa, , Japan
Miyata Ophthalmic Hospital /ID# 167707
Miyakonojō, , Japan
Duplicate_The Hospital of Hyogo College /ID# 166913
Nishinomiya-shi, , Japan
Osaka Hospital /ID# 164151
Osaka, , Japan
Yodogawa Christian Hospital /ID# 161741
Osaka, , Japan
Omihachiman Community Med Ctr /ID# 164978
Ōmihachiman, , Japan
Tosei General Hospital /ID# 167708
Seto, , Japan
Natl Defense Med College Hosp /ID# 162946
Tokorozawa, , Japan
Abbott Japan /ID# 147893
Tokyo, , Japan
Tokyo Shinjuku Medical Center /ID# 166934
Tokyo, , Japan
Tottori Municipal Hospital /ID# 159431
Tottori, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Namba K, Kaburaki T, Tsuruga H, Ogawa Y, Iwashita E, Goto H. Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients. Ophthalmol Ther. 2022 Jun;11(3):1147-1161. doi: 10.1007/s40123-022-00493-z. Epub 2022 Mar 19.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P15-665
Identifier Type: -
Identifier Source: org_study_id